ClinicalTrials.gg
CompletedNCT03934216Updated Mar 6, 2024Results posted

Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis

A Phase 2 interventional study of BMS-986165 and Placebo in Ulcerative Colitis, sponsored by Bristol-Myers Squibb. Completed at 107 sites in 13 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-06.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
131
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Colitis, Ulcerative by Bristol-Myers Squibb — 4 open to participants now, 5 under way, 1 of them phase 3. Colitis, Ulcerative · Bristol-Myers Squibb.

Enrollment
9th of 17
131 · median 131
Started
2019
with 1 other
Phase 2
7 of 22
none open now
Registered
12th of 22
by date

Among the 22 studies in Colitis, Ulcerative by Bristol-Myers Squibb, this one is the 9th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2019, is one of 7 in phase 2, and was the 12th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

4 of the 22 studies in Colitis, Ulcerative by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Colitis, Ulcerative by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of oral deucravacitinib in participants with moderate to severe ulcerative colitis (UC).

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Must have active ulcerative colitis (UC) extending ≥ 15 cm from the anal verge and confirmed by a screening/baseline colonoscopy/sigmoidoscopy prior to the randomization visit
  • Must have documented diagnosis of UC of at least 3 months' duration prior to screening
  • Must have active moderate to severe UC, as defined by a modified Mayo score of 5 to 9 points, inclusive, which includes a stool frequency (SF) subscore of ≥ 2, and a rectal bleeding (RB) subscore ≥ 1, and a screening endoscopic (ES) subscore of ≥ 2

Exclusion criteria

Exclusion Criteria:

  • Previous/current documented diagnosis of CD, indeterminate colitis, ischemic colitis, or pseudomembranous colitis (other than associated with Clostridium difficile [C. difficile])
  • Stool positive for C. difficile toxin at screening visit
  • Current or recent (within 12 weeks prior to the randomization visit) evidence of fulminant colitis, abdominal abscess, toxic megacolon, or bowel perforation

Other protocol-defined inclusion/exclusion criteria apply

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    BMS-986165

    Drug: BMS-986165

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Specified Dose on Specified Days

    Also known as: Deucravacitinib

  • OtherPlacebo

    Specified Dose on Specified Days

06

What researchers measure

Primary outcomes

  1. Clinical Remission Response Rate at Week 12

    Clinical remission response rate is the percentage of participants achieving clinical remission, defined as absolute total Mayo Score and absolute Mayo endoscopy, stool frequency, rectal bleeding. Will be calculated using a modified Mayo score with the following: Stool Frequency (SF) sub score ≤ 1, with ≥ 1 point decrease from baseline, and Rectal Bleeding (RB) sub score = 0, and Endoscopic (ES) sub score ≤ 1 (modified, excludes friability) The modified Mayo score (0 to 9 points) is the sum of 3 components: the SF, RB, and ES sub scores Modified Mayo Score: The modified Mayo score is a 9-point scale; a score of 5 to 9 points (inclusive), which is required for randomization, denotes moderate to severe disease (by protocol definition). considered in clinical remission if a Mayo Score of less than or equal to 2 with no individual sub score greater than 1

    Time frame: From first dose to 12 weeks.

Secondary outcomes

  1. Clinical Response Rate at 12 Weeks

    Clinical response is defined as percentage of participants with a reduction in total Mayo Score and reduction in rectal bleeding subscore Will be defined as the following: A decrease from baseline in the modified Mayo score of ≥ 2 points, and A decrease from baseline in the modified Mayo score ≥ 30%, and A decrease in rectal bleeding(RB) subscore of ≥ 1 point or absolute RB subscore ≤ 1

    Time frame: From first dose to 12 weeks

  2. Endoscopic Response at Week 12

    Endoscopic response will be defined as percentage of participants with a reduction in the total Ulcerative Colitis Endoscopic Index of Severity score. The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) scale: Vascular Pattern: * Normal (score 0) * patchy obliteration (score 1) * Obliterated (score 2) Bleeding * None (score 0) * Mucosal (score 1) * Luminal mild (score 2) * Luminal Moderate or severe (score 3) Erosions and Ulcers * None (score 0) * Erosions ( score 1) * Superficial Ulcer (2) * Deep Ulcer (score 3) A total score represents the following: remission (0-1); mild (2-4); moderate (5-6); and severe (7-8).

    Time frame: up to 12 Weeks

  3. Histological Improvement Response Rate at 12 Weeks

    Histologic improvement is defined as percentage of participants with a Geboes score of ≤ 3.1 Neutrophils \<5% of crypts, with no crypt destruction, erosions, ulcerations, and granulation tissue. Achieving the following scores for the corresponding grades of the Geboes score: * Score of 0 or 1 for Grade 3 (neutrophils in the epithelium: none or \< 5% crypts involved), and * Score of 0 for Grade 4 (crypt destruction: none), and * Score of 0 Grade 5 (erosion or ulceration: no erosions, ulcerations, or granulation tissue) grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher score indicates more severe disease

    Time frame: up to 12 Weeks

07

Results

Posted Jul 6, 2022

Participant flow

Participant flow — Overall Study
MilestoneTreatmentPlacebo
Started8843
Completed3012
Not completed5831
Withdrew: Other reasons55
Withdrew: Adverse event2211
Withdrew: Lack of efficacy87
Withdrew: Lost to follow-up20
Withdrew: Non-compliance with study drug11
Withdrew: Pregnancy10
Withdrew: Withdrawal by subject186
Withdrew: Randomized but not treated11

Outcome measures

PrimaryClinical Remission Response Rate at Week 12

Clinical remission response rate is the percentage of participants achieving clinical remission, defined as absolute total Mayo Score and absolute Mayo endoscopy, stool frequency, rectal bleeding. Will be calculated using a modified Mayo score with the following: Stool Frequency (SF) sub score ≤ 1, with ≥ 1 point decrease from baseline, and Rectal Bleeding (RB) sub score = 0, and Endoscopic (ES) sub score ≤ 1 (modified, excludes friability) The modified Mayo score (0 to 9 points) is the sum of 3 components: the SF, RB, and ES sub scores Modified Mayo Score: The modified Mayo score is a 9-point scale; a score of 5 to 9 points (inclusive), which is required for randomization, denotes moderate to severe disease (by protocol definition). considered in clinical remission if a Mayo Score of less than or equal to 2 with no individual sub score greater than 1

Time frame:
From first dose to 12 weeks.
Reported as:
Number · Percentage of Participants
Clinical Remission Response Rate at Week 12
Percentage of ParticipantsTreatmentPlacebo
Clinical Remission Response Rate at Week 1214.8 (7.4 to 22.2)16.3 (5.2 to 27.3)
Statistical analysis
  • Treatment vs Placebo · Stratified Cochran-Mantel-Haenszel · p = 0.5935 · Odds ratio (or): 0.9 · 95% CI 0.3 to 2.4
SecondaryClinical Response Rate at 12 Weeks

Clinical response is defined as percentage of participants with a reduction in total Mayo Score and reduction in rectal bleeding subscore Will be defined as the following: A decrease from baseline in the modified Mayo score of ≥ 2 points, and A decrease from baseline in the modified Mayo score ≥ 30%, and A decrease in rectal bleeding(RB) subscore of ≥ 1 point or absolute RB subscore ≤ 1

Time frame:
From first dose to 12 weeks
Reported as:
Number · Percentage of participants
Clinical Response Rate at 12 Weeks
Percentage of participantsTreatmentPlacebo
Clinical Response Rate at 12 Weeks37.5 (27.4 to 47.6)32.6 (18.6 to 46.6)
Statistical analysis
  • Treatment vs Placebo · Stratified Cochran-Mantel-Haenszel · p = 0.3051 · Odds ratio (or): 1.2 · 95% CI 0.6 to 2.7
SecondaryEndoscopic Response at Week 12

Endoscopic response will be defined as percentage of participants with a reduction in the total Ulcerative Colitis Endoscopic Index of Severity score. The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) scale: Vascular Pattern: * Normal (score 0) * patchy obliteration (score 1) * Obliterated (score 2) Bleeding * None (score 0) * Mucosal (score 1) * Luminal mild (score 2) * Luminal Moderate or severe (score 3) Erosions and Ulcers * None (score 0) * Erosions ( score 1) * Superficial Ulcer (2) * Deep Ulcer (score 3) A total score represents the following: remission (0-1); mild (2-4); moderate (5-6); and severe (7-8).

Time frame:
up to 12 Weeks
Reported as:
Number · Percentage of Participants
Endoscopic Response at Week 12
Percentage of ParticipantsTreatmentPlacebo
Endoscopic Response at Week 1219.3 (11.1 to 27.6)27.9 (14.5 to 41.3)
Statistical analysis
  • Treatment vs Placebo · Stratified Cochran-Mantel-Haenszel · p = 0.8764 · Odds ratio (or): 0.6 · 95% CI 0.3 to 1.4
SecondaryHistological Improvement Response Rate at 12 Weeks

Histologic improvement is defined as percentage of participants with a Geboes score of ≤ 3.1 Neutrophils \<5% of crypts, with no crypt destruction, erosions, ulcerations, and granulation tissue. Achieving the following scores for the corresponding grades of the Geboes score: * Score of 0 or 1 for Grade 3 (neutrophils in the epithelium: none or \< 5% crypts involved), and * Score of 0 for Grade 4 (crypt destruction: none), and * Score of 0 Grade 5 (erosion or ulceration: no erosions, ulcerations, or granulation tissue) grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher score indicates more severe disease

Time frame:
up to 12 Weeks
Reported as:
Number · Percentage of Participants
Histological Improvement Response Rate at 12 Weeks
Percentage of ParticipantsTreatmentPlacebo
Histological Improvement Response Rate at 12 Weeks21.6 (13.0 to 30.2)16.3 (5.2 to 27.3)
Statistical analysis
  • Treatment vs Placebo · Stratified Cochran-Mantel-Haenszel · p = 0.2235 · Odds ratio (or): 1.4 · 95% CI 0.5 to 3.8

Adverse events

Collected over Adverse Events and Serious Adverse Events: (From first dose to last dose + 100 days): Approximately 104 Weeks All-Cause mortality (From randomization to end of study): Approximately 104 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment2/87 (2.3%)19/87 (21.8%)64/87 (73.6%)
Placebo0/10 (0%)2/10 (20%)6/10 (60%)
BMS-986165 6mg BID During OL Period After Receiving Placebo in Induction Period0/32 (0%)4/32 (12.5%)22/32 (68.8%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventTreatmentPlaceboBMS-986165 6mg BID During OL Period After Receiving Placebo in Induction Period
Colitis ulcerativeGastrointestinal disorders3/871/102/32
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/871/100/32
COVID-19 pneumoniaInfections and infestations8/870/100/32
Congenital aural fistulaCongenital, familial and genetic disorders0/870/101/32
Enterocolitis infectiousInfections and infestations0/870/101/32
AnaemiaBlood and lymphatic system disorders1/870/100/32
Abdominal painGastrointestinal disorders1/870/100/32
ConstipationGastrointestinal disorders1/870/100/32
Impaired gastric emptyingGastrointestinal disorders1/870/100/32
Anal abscessInfections and infestations1/870/100/32
Most frequent other events
Showing 10 of 35
Most frequent other events
EventTreatmentPlaceboBMS-986165 6mg BID During OL Period After Receiving Placebo in Induction Period
Colitis ulcerativeGastrointestinal disorders17/872/108/32
COVID-19Infections and infestations13/870/106/32
PyrexiaGeneral disorders3/870/105/32
RashSkin and subcutaneous tissue disorders13/870/103/32
NasopharyngitisInfections and infestations6/870/104/32
ArthralgiaMusculoskeletal and connective tissue disorders5/870/104/32
AcneSkin and subcutaneous tissue disorders9/870/102/32
AnaemiaBlood and lymphatic system disorders4/871/102/32
Abdominal distensionGastrointestinal disorders0/871/100/32
Aphthous ulcerGastrointestinal disorders5/871/102/32

Baseline characteristics

Age, Continuous
Age, Continuous(Years)TreatmentPlaceboTotal
Mean41.6 ± 14.8140.3 ± 13.9141.2 ± 14.48
Sex: Female, Male
Sex: Female, Male(Participants)TreatmentPlaceboTotal
Female401454
Male482977
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TreatmentPlaceboTotal
Hispanic or Latino325
Not Hispanic or Latino8341124
Unknown or Not Reported202
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TreatmentPlaceboTotal
American Indian or Alaska Native000
Asian3710
Native Hawaiian or Other Pacific Islander000
Black or African American527
White8034114
More than one race000
Unknown or Not Reported000
08

Study locations

107 sites
  • Connecticut Clinical Research Foundation
    Bristol, Connecticut 06010, United States
  • University of Florida
    Gainesville, Florida 32610-0316, United States
  • University of Florida
    Gainesville, Florida 32611, United States
  • Local Institution - 0048
    New Port Richey, Florida 34653, United States
  • Local Institution - 0044
    Sweetwater, Florida 33172, United States
  • Local Institution - 0011
    Suwanee, Georgia 30024, United States
  • Local Institution - 0121
    Glenview, Illinois 60026, United States
  • Texas Digestive Disease Consultants - Gastroenterology Associates - Baton Rouge
    Baton Rouge, Louisiana 70809, United States
  • Local Institution - 0018
    Shreveport, Louisiana 71103, United States
  • Local Institution - 0047
    Chevy Chase, Maryland 20815, United States
  • Infusion Associates
    Grand Rapids, Michigan 49525, United States
  • Mayo Clinic - Rochester
    Rochester, Minnesota 55905, United States
  • Local Institution - 0002
    Las Vegas, Nevada 89123, United States
  • Local Institution - 0049
    Lake Success, New York 11042, United States
  • New York University Langone Medical Center
    New York, New York 10016, United States
  • Consultants for Clinical Research
    Cincinnati, Ohio 45218, United States
  • Penn State Health Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Local Institution - 0074
    Charleston, South Carolina 29425, United States
  • Rapid City Medical Center
    Rapid City, South Dakota 57701, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Local Institution - 0097
    Garland, Texas 75044, United States
  • Local Institution - 0008
    Houston, Texas 77090, United States
  • Gastroenterology Research of San Antonio
    San Antonio, Texas 78229, United States
  • Local Institution - 0106
    San Antonio, Texas 78229, United States
  • Texas Digestive Disease Consultants - Southlake
    Southlake, Texas 76092, United States
  • Local Institution - 0116
    Tyler, Texas 75701, United States
  • Local Institution - 0096
    Seattle, Washington 98101, United States
  • Swedish First Hill Campus
    Seattle, Washington 98104, United States
  • Local Institution - 0122
    Vancouver, Washington 98664, United States
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Local Institution - 0071
    Bedford Park, South Australia 5042, Australia
  • Local Institution - 0108
    Melbourne, Victoria 3181, Australia
  • Fiona Stanley Hospital
    Murdoch, Western Australia 6150, Australia
  • Local Institution - 0039
    Antwerpen, 2018, Belgium
  • Local Institution - 0065
    Brussels, 1000, Belgium
  • Clinique du MontLegia - CHC
    Liege, 4000, Belgium
  • Hepato-Gastroenterology HK
    Hradec Kralove, 500 12, Czechia
  • Nemocnice Slany
    Slany, 274 01, Czechia
  • Centre Hospitalier Universitaire de Montpellier
    Montpellier cedex 5, 34295, France
  • Centre Hospitalier Lyon Sud
    Pierre Benite Cedex, 69495, France
  • Centre Hospitalier Universitaire de Saint-Etienne - Hopital Nord
    Saint-Etienne, 42055, France
  • Local Institution
    Toulouse cedex 9, 31059, France
  • Charite Universitatsmedizin Berlin - Campus Virchow-Klinikum
    Berlin, 13353, Germany
  • Universitatsklinikum Carl Gustav Carus Dresden
    Dresden, 01307, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Local Institution - 0070
    Kiel, 24105, Germany
  • Local Institution - 0062
    Leipzig, 04103, Germany
  • Universitatsklinik Ulm
    Ulm, 89081, Germany
  • Magyar Honvedseg-Egeszsegugyi Kozpont
    Budapest, 1062, Hungary
  • Local Institution - 0042
    Budapest, 1088, Hungary
  • Local Institution - 0024
    Budapest, 1097, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • Bugat Pal Korhaz
    Gyongyos, 3200, Hungary
  • Local Institution - 0033
    Rozzano, Milano 20089, Italy
  • Azienda Ospedaliero-Universitaria di Bologna - Policlinico SantOrsola-Malpighi
    Bologna, 40126, Italy
  • Local Institution - 0005
    Catanzaro, 88100, Italy
  • Clinica Medica Azienda Ospedaliera Universitaria
    Messina, 98125, Italy
  • Azienda Ospedaliera di Padova
    Padova, 35128, Italy
  • Local Institution - 0027
    Pavia, 27100, Italy
  • Policlinico Universitario Campus Bio-Medico
    Roma, 00128, Italy
  • Local Institution - 0046
    Roma, 00133, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli
    Roma, 00168, Italy
  • National Hospital Organization Hirosaki National Hospital
    Hirosaki, Aomori 036-8545, Japan
  • Fukuoka University Chikushi Hospital
    Chikushino, Fukuoka 818-8502, Japan
  • Local Institution - 0078
    Kurume, Fukuoka 830-0011, Japan
  • National Hospital Organization Takasaki General Medical Center
    Takasaki, Gunma 3700829, Japan
  • Hyogo College of Medicine Hospital
    Nishinomiya, Hyogo 663-8501, Japan
  • Local Institution - 0081
    Sagamihara-shi, Kanagawa 2520375, Japan
  • Shiga University of Medical Science Hospital
    Otsu, Shiga 520-2192, Japan
  • Local Institution - 0066
    Bunkyo-ku, Tokyo 113-8519, Japan
  • Local Institution - 0080
    Minato-ku, Tokyo 105-8471, Japan
  • Local Institution - 0069
    Saga, 849-8501, Japan
  • Local Institution - 0064
    Daegu, 42415, Korea, Republic of
  • Local Institution
    Daegu, 700-712, Korea, Republic of
  • Local Institution
    Daegu, 700-721, Korea, Republic of
  • Local Institution
    Incheon, 22332, Korea, Republic of
  • Local Institution
    Seoul, 137-701, Korea, Republic of
  • Local Institution
    Seoul, 156-755, Korea, Republic of
  • Local Institution - 0091
    Bydgoszcz, 85-231, Poland
  • Local Institution - 0013
    Bydgoszcz, 85-794, Poland
  • Local Institution - 0100
    Lodz, 90-153, Poland
  • Local Institution - 0045
    Lodz, 90-302, Poland
  • Local Institution - 0098
    Nowy Targ, 34-400, Poland
  • Local Institution - 0094
    Piotrkow Trybunalski, 97-300, Poland
  • Local Institution - 0040
    Sopot, 81-756, Poland
  • Local Institution - 0053
    Szczecin, 71-434, Poland
  • Local Institution - 0014
    Tychy, 43 100, Poland
  • Centrum Zdrowia Matki Dziecka i Mlodziezy
    Warszawa, 00-635, Poland
  • Local Institution - 0088
    Warszawa, 00-728, Poland
  • Local Institution - 0095
    Warszawa, 02-798, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej VIVAMED Jadwiga Miecz
    Warszawa, 03-580, Poland
  • Local Institution - 0030
    Warszawa, 03-712, Poland
  • Local Institution - 0037
    Wroclaw, 53-114, Poland
  • Centrum Medyczne Oporow
    Wroclaw, 54-416, Poland
  • Nizhniy Novgorod Regional Clinical Hospital N.A. Semashko
    Nizhniy Novgorod, 603126, Russian Federation
  • Local Institution - 0020
    Novosibirsk, 630005, Russian Federation
  • Novosibirsk State Regional Clinical Hospital
    Novosibirsk, 630087, Russian Federation
  • Local Institution - 0092
    Novosibirsk, 630099, Russian Federation

Showing the first 100 of 107 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Jun 2021, 23 months.

Results were first posted in Jul 2022, 1 year after primary completion.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 23 months is below that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2019
First posted
May 1, 2019
StartActual
Jul 1, 2019
Primary completionActual
Jun 13, 2021
CompletionActual
Apr 4, 2023
Results first posted
Jul 6, 2022
Last update
Mar 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03934216
Responsible party
Sponsor
First posted
May 1, 2019
Start date
Jul 1, 2019
Primary completion
Jun 13, 2021
Completion
Apr 4, 2023
Results posted
Jul 6, 2022
Last update
Mar 6, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion